Educational Appendix

A measure of the binding constant between a single antigen combining site on an antibody and a monovalent antigenic determinant.
Allelic exclusion
The ability of heterozygous lymphoid cells to produce only one allelic form of antigen-specific receptor when they have the genetic endowment to produce both. Genes other than those for the specific receptors are usually expressed codominantly. In B lymphocytes, successful heavy chain gene rearrangement of the genetic material from one chromosome results in the shutting down of rearrangement of genetic material from the second chromosome. If no successful rearrangement occurs, rearrangement of genetic material on the second chromosome takes place. If no successful rearrangement occurs on either chromosome, the cell dies. As a result of allelic exclusion, all the antigen receptors on an individual lymphocyte will have the same amino acid sequence in the variable domain of the heavy chain protein. As the specificity of the antigen receptor is modulated by the variable domain of the light chain encoded by one of the immunoglobulin light chain loci, the specificities of B cells containing the same heavy chain recombination event can differ according to their light chain recombination event.
An allergen is a type of antigen that produces an abnormally vigorous immune response in which the immune system fights off a perceived threat that would otherwise be harmless to the body. Such reactions are called allergies. Specifically, an allergen is an antigen capable of stimulating a type-I hypersensitivity reaction in atopic individuals through Immunoglobulin E (IgE) responses. Most humans mount significant IgE responses only as a defense against parasitic infections. However, some individuals may respond to many common environmental antigens. This hereditary predisposition is called atopy. In atopic individuals, non-parasitic antigens stimulate inappropriate IgE production, leading to type I hypersensitivity.
Allergies are a number of conditions caused by hypersensitivity of the immune system to something in the environment that usually causes little problem in most people. These diseases include hay fever, food allergies, atopic dermatitis, allergic asthma, and anaphylaxis. In the early stages of allergy, a type I hypersensitivity reaction against an allergen encountered for the first time and presented by an antigen-presenting cell causes a response in an immune cell called a TH2 lymphocyte. These TH2 cells interact with B cells and stimulate production of a large amount of IgE antibodies. Secreted IgE circulates in the blood and binds to immune cells called mast cells and basophils, which are both involved in the acute inflammatory response. The IgE-coated cells, at this stage, are sensitized to the allergen. If later exposure to the same allergen occurs, the allergen can bind to the IgE molecules held on the surface of the mast cells or basophils, cross-linking them and activating the sensitized cell. Activated mast cells and basophils undergo a process called degranulation, during which they release histamine and other inflammatory chemical mediators (cytokines, interleukins, leukotrienes, and prostaglandins) from their granules into the surrounding tissue causing several systemic effects, such as vasodilation, mucous secretion, nerve stimulation, and smooth muscle contraction. After the acute response subsides, late-phase responses can often occur due to the migration of other leukocytes such as neutrophils, lymphocytes, eosinophils and macrophages to the initial site. This reaction is usually seen 2-24 hours after the original reaction. Cytokines from mast cells may play a role in the persistence of long-term effects.
Having a genetic dissimilarity within the same species.
A tissue transplant (graft) between two genetically nonidentical members of a species.
Antigenic determinants that are present in allelic (alternate) forms. When used in association with immunoglobulin, allotypes describe allelic variants of immunoglobulins detected by antibodies raised between members of the same species.
Alternate (Alternative) pathway
 The mechanism of complement activation that does not involve activation of the C1, C4, C2 pathway by antigen-antibody complexes, and begins with the activation of C3.
Substance capable of releasing histamine from mast cells.
Immediate hypersensitivity response to antigenic challenge, mediated by IgE and mast cells. It is a life-threatening allergic reaction, caused by the release of pharmacologically active agents.
Serum protein formed in response to immunization; antibodies are generally defined in terms of their specific binding to the immunizing antigen.
Antibody-dependent, cell-mediated cytotoxicity (ADCC)
A phenomenon in which target cells, coated with antibody, are destroyed by specialized killer cells (NK cells and macrophages), which bear receptors for the Fc portion of the coating antibody (Fc receptors). These receptors allow the killer cells to bind to the antibody-coated target.
 Any foreign material that is specifically bound by specific antibody or specific lymphocytes; also used loosely to describe materials used for immunization. Antigens may also be immunogens if they are able to trigger an immune response, or haptens if not.
Antigen processing:
Large molecules are broken down (processed) within macrophages into peptides and presented within the groove of MHC molecules.
Antigen receptor
The specific antigen-binding receptor on T or B lymphocytes; these receptors are transcribed and translated from rearrangements of V genes.
Antigen-binding site
 The part of an immunoglobulin molecule that binds antigen specifically.
Antigen-presenting cell (APC)
An antigen-presenting cell or accessory cell is a cell that processes antigens and presents them on their cell surface complexed with major histocompatibility complexes (MHCs) for T cells to recognize using their T cell receptors (TCRs). Almost all cell types can serve as some form of APC, and they are found in a variety of tissue types. Professional antigen-presenting cells, including macrophages, B cells and dendritic cells, present foreign antigens to helper T cells, while other cell types can present antigens originating inside the cell to cytotoxic T cells. Antigen-presenting cells are vital for an effective adaptive immune response that is specific and can be directed against either intracellular and extracellular pathogens. It is also involved in defense against tumors.
A term used by allergists to describe IgE-mediated anaphylactic responses in humans, usually genetically determined.
A tissue transplant from one area to another on a single individual.
Autoimmunity (autoallergy)
An immune response to "self" tissues or components. Such an immune response may have pathological consequences leading to autoimmune diseases.
In antibody-antigen interactions multiple antigen-binding sites simultaneously interact with the target antigenic epitopes, often in multimerized structures. Individually, each binding interaction may be readily broken, however, when many binding interactions are present at the same time, transient unbinding of a single site does not allow the molecule to diffuse away, and binding of that weak interaction is likely to be restored. Each antibody has at least two antigen-binding sites, therefore antibodies are bivalent to multivalent. Avidity (functional affinity) is the accumulated strength of these multiple affinities. For example IgM is said to have low affinity but high avidity because it has 10 weak binding sites for antigen as opposed to the 2 stronger binding sites of IgG, IgE and IgD with higher single binding affinities.
AXL receptor tyrosine kinase
AXL is a member of the TAM receptor tyrosine kinase subfamily (TYRO3, AXL and MER). AXL transduces signals from the extracellular matrix into the cytoplasm by binding growth factors like vitamin K-dependent protein growth-arrest-specific gene 6 (GAS6). It is involved in the stimulation of cell proliferation; Axl is a chronic myelogenous leukemia-associated oncogene and also associated with colon cancer and melanoma. This receptor can also mediate cell aggregation by homophilic binding. The Axl gene is evolutionarily conserved between vertebrate species, and has two different alternatively spliced transcript variants.
B lymphocyte (B cell)
The precursors of antibody-forming plasma cells; these cells carry immunoglobulin and class II MHC (major histocompatibility complex) antigens on their surfaces.
A granulocyte that can secrete heparin, histamine and other vasoactive amines. Within tissues, these cells are known as mast cells.
Blocking antibody
A functional term for an antibody molecule capable of blocking the interaction of antigen with other antibodies or with cells.
A large immunogenic molecule or particle to which an antigenic determinant is attached, allowing the determinant to become immunogenic.
Cell-mediated cytotoxicity (CMC)
Killing (lysis) of a target cell by an effector lymphocyte.
Cell-mediated immunity (CMI)
Immune reaction mediated by T cells, in contrast to humoral immunity which is antibody mediated. Also referred to as delayed-type hypersensitivity.
Migration of cells along a concentration gradient of an attractant.
Chimeric antibody
An antibody comprised of human and non human components; usually refers to an antibody with a mouse variable region and human constant region.
Class I, II and III MHC molecules
Proteins encoded by genes in the major histocompatibility complex. Class I molecules are designated HLA-A, B, or C. Class II molecules are designated DP, DQ or DR.
Class switch
See isotype switch.
Classical pathway
The mechanism of complement activation initiated by antigen-antibody aggregates and proceeding by way of C1, C4 and C2.
Clonal deletion
The loss of lymphocytes of a particular specificity due to contact with either "self" or artificially introduced antigen.
Clonal selection theory
The prevalent concept that specificity and diversity of an immune response are the result of selection by antigen of specifically reactive clones from a large repertoire of preformed lymphocytes, each with individual specificities.
Cluster determinant (CD)
Cluster of antigens with which antibodies react that characterize a cell surface marker.
Combinatorial joining
The joining of segments of DNA to generate essentially new genetic information, as occurs with Ig genes during the development of B cells. Combinatorial joining allows multiple opportunities for 2 sets of genes to combine in different ways.
 A series of serum proteins involved in the mediation of immune reactions. The complement cascade is triggered classically by the interaction of antibody with specific antigen.
Complement components
An enzymatic system of serum proteins triggered by the classical and alternative pathways, and resulting in target cell lysis, phagocytosis, opsonization and chemotaxis.
Complement receptor
A structure found on erythrocytes, lymphocytes, neutrophils, monocytes and macrophages that binds C3 fragments.
Constant region (C region)
The invariant carboxyl-terminal portion of an antibody molecule, as distinct from the variable region which is at the amino-terminal of the chain.
The ability of an antibody, specific for one antigen, to react with a second antigen; a measure of relatedness between two different antigenic substances.
CTLA4 (cytotoxic T-lymphocyte-associated protein 4) is a member of the immunoglobulin superfamily that is expressed on the surface of Helper T cells and transmits an inhibitory signal to T cells. CTLA4 is similar to the T-cell co-stimulatory protein, CD28, and both molecules bind to CD80 and CD86, also called B7-1 and B7-2 respectively, on antigen-presenting cells. CTLA4 transmits an inhibitory signal to T cells, whereas CD28 transmits a stimulatory signal. Blocking CTLA4 using antagonistic antibodies has been shown to help inhibit immune system tolerance to tumors and thereby offers a promising immunotherapy strategy for patients with cancer.
Soluble substances secreted by cells, which have a variety of effects on other cells, e.g. Interleukin 1 (Il-1).
Cytotoxic (Cytolytic) T cell
 Cell that kills target cells bearing appropriate antigen within the groove of an MHC class I molecule that is identical to that of the T cell.
D gene
A small segment of immunoglobulin heavy-chain and T-cell receptor DNA, coding for the third hypervariable region of most receptors.
Delayed type hypersensitivity (DTH)
A T cell-mediated reaction to antigen, which takes 24-48 hours to develop fully, and which involves release of lymphokines and recruitment of monocytes and macrophages. Also called c cell-mediated immunity.
Part of the antigen molecule which binds to an antibody-combining site or to a receptor on T cells (see hapten and epitope).
Differentiation antigen
A cell surface antigenic determinant found only on cells of a certain lineage and at a particular developmental stage; used as an immunologic marker.
A compact segment of an immunoglobulin molecule, made up of about 110 amino acids around an S-S bond, and encoded by a unique segment of DNA, surrounded by nontranslated sequences.
DR antigens
MHC class II molecules found on B cells and antigen-presenting cells of humans.
Enchancing antibodies
Antibodies which enhance the survival of a graft or of a tumor.
Enzyme-linked immunosorbent assay (ELISA)
An assay in which an enzyme is linked to an antibody and a coloured substrate is used to measure the activity of bound enzyme and, hence, the amount of bound antibody.
A polymorphonuclear leukocyte with large eosinophilic (i.e. red) cytoplasmic granules.
Eosinophil chemotactic factor of anaphylaxis (ECF-A)
A substrate released from mast cells during anaphylaxis which attracts eosinophils.
 A single antigenic site on a complex antigenic molecule or particle.
Equivalence zone
 In a precipitin reaction, the region in which the concentration of antigen and antibody leads to maximal precipitation.
A fragment of an antibody containing two antigen-binding sites generated by cleavage of the antibody molecule with the enzyme pepsin which cuts at the hinge region C-terminally to the inter-H-chain disulphide bond.
Fragment of antibody containing the antigen-binding site, generated by cleavage of the antibody with the enzyme papain, which cuts at the hinge region N-terminally to the inter-H-chain disulphide bond and generates two Fab fragments from one antibody molecule.
 Fragment of antibody without antigen-binding sites, generated by cleavage with papain; the Fc fragment contains the C-terminal domains of the heavy immunoglobulin chains.
Fc receptor (FcR)
 A receptor on a cell surface with specific binding affinity for the Fc portion of an antibody molecule. Fc receptors are found on many types of cells.


Jay Short,
Chairman, Chief Executive Officer & Cofounder

Dr. Short is a cofounder of BioAtla© and co-inventor of the BioAtla's patented Conditionally Active Biologics (CAB) platform. He also cofounded Diversa Corporation (now BASF), a pioneering developer of enzymes, antibodies and biologically active compounds, and served in multiple roles including CEO, President and CTO from 1994 to 2005. He led Diversa's public offering, raising over $200 million, which was the largest biotechnology IPO at that time. Prior to Diversa, Dr. Short served as President of Stratacyte, an antibody engineering company and subsidiary of Stratagene (now Agilent), which together with Scripps Clinic was the first to clone and screen human antibody libraries in E. coli. During this time he also served as VP of R&D and Operations for Stratagene Cloning Systems. Dr. Short received his B.A in Chemistry with Honors from Taylor University. At Case Western Reserve University he received his Ph.D. in Biochemistry with additional studies in Macromolecular Science. He is the author of more than 100 publications and is the inventor of over 500 issued patents.

In 2006, Dr. Short was shortlisted by the editors of Nature Biotechnology as one of the people who made the most significant contribution to biotech in the past decade. He is the recipient of numerous other awards, including Ernst & Young's Entrepreneur of the Year Award, the American Chemical Society's Henry F. Whalen, Jr. Award for Business Development, Adaptive Business Leaders' Innovations in HealthCare Gold Award, two of Connect's first place Most Innovative Product Awards, and in 2010 received an international Best-of-the-Best award from the Young Presidents Organization (YPO). Dr. Short's board experience includes 15 years as a director of Invitrogen (now Thermo Fisher), Senomyx, and Taxon Biosciences (now Dupont). He is a member of YPO/WPO and a founder of Capia IP and the E.O. Wilson Biodiversity Foundation. Dr. Short serves as an advisor to educational, commercial, scientific and charitable organizations.

Carolyn Anderson Short


Carolyn Short is a co-founder of BioAtla©, and served as the head of global intellectual property and business strategy for the company from its inception through its IPO until May 2021. While at BioAtla, prior to the IPO, she helped the company raise over $100M out of partnerships with Chinese biopharma companies and investors. She is also a founder, President and COO of Himalaya Therapeutics SEZC. Carolyn has decades of experience in business, intellectual property, and licensing/technology transfer matters in a variety of industries, including healthcare, life science, energy, industrial chemicals, agriculture, foods & flavors, diagnostics, research reagents and cleantech. She holds a degree in Biochemistry & Cell Biology from the University of California, San Diego, and is a registered patent agent with the United States Patent & Trademark Office.

BioAtla's mascot George
Germ line
Refers to genes in germ cells as opposed to somatic cells, that is, genes in their unrearranged state rather than those rearranged for production of a protein.
H-2 complex
The major histocompatibility complex situated on chromosome 17 of the mouse; contains subregions K, I and D.
A particular combination of closely linked genes on a chromosome inherited from one patient.
A compound, usually of low molecular weight, that is not itself immunogenic but that, after conjugation to a carrier protein or cells, becomes immunogenic and induces antibody, which can bind the hapten alone in the absence of carrier.
Heavy chain (H chain)
The larger of the two types of chains that comprise a normal immunoglobulin or antibody molecule.
Helper T cells
A class of T cells which help trigger B cells to make antibody against thymus-dependent antigens. Helper T cells also help generate cytotoxic T cells.
Hinge region
A flexible, open segment of an antibody molecule that allows bending of the molecule. The hinge region is located between Fab and Fc and is susceptible to enzymatic cleavage.
Literally, the ability of tissues to get along; in immunology, it means identity in all transplantation antigens. These antigens, in turn, are collectively referred to as histocompatibility antigens.
HLA complex
See ‘Major histocompatibility complex'.
A technique for inserting non-human complementarity-determining regions (CDRs) into human framework regions.
Humoral immunity
Any immune reaction that can be transferred with immune serum is termed humoral immunity (as opposed to cell-mediated immunity). In general, this term refers to resistance that results from the presence of specific antibody.
A hybrid cell that results from the fusion of an antibody-secreting cell with a malignant cell; the progeny secrete antibody without stimulation and proliferate continuously both in vivo and in vitro.
State of reactivity to antigen that is greater than normal for the antigenic challenge; hypersensitivity is the same as allergy and denotes a deleterious outcome rather than a protective one.
Hypervariable regions
Portions of the light and heavy immunoglobulin chains that are highly variable in amino acid sequence from one immunoglobulin molecule to another, and that, together, constitute the antigen-binding site of an antibody molecule. Also, portions of the T-cell receptor which constitute the antigen-binding site.
"Immune response-associated" proteins, found on B cells and antigen-presenting cells of mice; an old term now replaced with MHC (major histocompatibility complex) class II molecules.
The combined antigenic determinants (idiotopes) found on antibodies of an individual that are directed at a particular antigen; such antigenic determinants are found only in the variable region.
Immune adherence
The adherence of particulate antigen coated with C3b to tissue having cells with C3b receptors.
Immune complex
Antigen bound to antibody.
Immune modulators
Substances that control the expression of the immune response.
Immune response (Ir) gene
A gene controlling an immune response to a particular antigen; most genes of this type are in the MHC (major histocompatibility complex), and the term is rarely used to describe other types of Ir genes outside the MHC.
A substance capable of inducing an immune response (as well as reacting with the products of an immune response). Compare with antigen.
Immunoglobulin (Ig)
 A general term for all antibody molecules. Each Ig unit is made up of two heavy chains and two light chains and has two antigen- binding sites.
A group of proteins having antiviral activity and capable of enhancing and modifying the immune response.
Glycoproteins secreted by a variety of leukocytes which have effects on other leukocytes.
Internal image
A spatial configuration of the combining site of an anti-idiotype antibody which resembles the epitope to which the idiotype is directed.
Antibodies to major red blood cell antigens present normally as a result of inapparent immunization by cross-reactive antigens in bacteria, food, etc.
Classes of antibody that differ in the constant region of their heavy chain (Fc portion); distinguishable also on the basis of reaction with antisera raised in another species. These differences also result in different biological activities of the antibodies.
J chain (joining chain)
A polypeptide involved in the polymerization of immunoglobulin molecules IgM and IgA.
J gene
A gene segment coding for the J or joining segment in immunoglobulin DNA; V genes translocate to J segments in L chains, and to D and J segments in H chains. Also, codes for a portion of the T-cell receptor.
K cell
An effector lymphocyte with Fc receptors which allow it to bind to and kill antibody-coated target cells.
Killer T cell
A T cell with a particular immune specificity and an endogenously produced receptor for antigen, capable of specifically killing its target cell after attachment to the target cell by this receptor. Also called cytotoxic T cell.
Light chain (L chain)
The light chain of immunoglobulin is a structural feature that occurs in two forms: kappa and lambda.
Small cell with virtually no cytoplasm, found in blood, in all tissue, and in lymphoid organs, such as lymph nodes, spleen, and Peyer's patches, and bears antigen-specific receptors.
 Soluble substances secreted by lymphocytes, which have a variety of effects on lymphocytes and other cell types.
A large phagocytic cell of the mononuclear series found within tissues. Properties include phagocytosis, and antigen presentation to T cells.
Macrophage-activating factor (MAF)
Actually several lymphokines, including interferon, released by activated T cells, which together induce activation of macrophages, making them more efficient in phagocytosis and cytotoxicity.
Major histocompatibility complex (MHC)
A cluster of genes on chromosome 6 in humans, encoding cell surface molecules that are polymorphic and that code for antigens which lead to rapid graft rejection between members of a single species which differ at these loci. Several classes of protein such as MHC class I and II proteins are encoded in this region. These in humans, are known as ‘Human leukocyte antigens' (HLA).
Mast cell
Tissue located cell probably derived from basophils. Possesses receptor for Fc of IgE. Participates in ‘Immediate hypersensitivity' reactions.
In the immune system, memory denotes an active state of immunity to a specific antigen, such that a second encounter with that antigen leads to a larger and more rapid response.
MHC class I molecule
A molecule encoded to genes of the MHC which participates in antigen presentation to cytotoxic T (CD8+) cells.
MHC class II molecule
A molecule encoded by genes of the MHC which participates in antigen presentation to helper T (CD4+) cells.
MHC restriction
 The ability of T lymphocytes to respond only when they ‘see' the appropriate antigen in association with "self" MHC class I or class II proteins on the antigen presenting cells.
Migration inhibition factor (MIF)
A lymphokine that inhibits the motility of macrophages in culture.
Minor histocompatibility antigens
These antigens, encoded outside the MHC, are numerous, but do not generate rapid graft rejection or primary responses of T cells in vitro. They do not serve as restricting elements in cell interactions.
A substance that stimulates the proliferation of many different clones of lymphocytes.
Mixed lymphocyte reaction (MLR)
When lymphocytes from two individuals are cultured together, a proliferative response is generally observed, as the result of reactions of T cells of one individual to MHC antigens on the other individual's cells.
Literally, coming from a single clone. A clone is the progeny of a single cell. In immunology, monoclonal generally describes a preparation of antibody that is monogenous, or cells of a single specificity.
 Large circulating white cell, 2-10% of total white cells, phagocytic, indented nucleus. Migrates to tissues, where it is known as a macrophage.
Soluble substances secreted by monocytes, which have a variety of effects on other cells.
Murine antibody
An antibody derived solely from mouse proteins.
A tumor of plasma cells, generally secreting a single species of immunoglobulin.
NK cell
Naturally occurring, large, granular, lymphocyte-like killer cells that kill various tumour cells; they may play a role in resistance to tumors. Also, they participate in ADCC. They do not exhibit antigenic specificity, and their number does not increase by immunization.
Null cells
An early population of lymphocytes bearing neither T-cell nor B-cell differentiation antigens.
An antibody combining site that is complementary to an epitope.
Passive immunization
Immunization by the administration of preformed antibody into a nonimmune individual.
The engulfment of a particle or a microorganism by leukocytes.
Plasma cell
End-stage differentiation of a B cell to an antibody-producing cell.
Polyclonal activator
A substance that induces activation of many individual clones of either T or B cells. See Mitogen.
Polymorphonuclear leukocyte
White cell, granular cytoplasm. Neutral staining (neutrophil) - most frequent, phagocytic. Basophilic staining - basophil q.v. Eosinophilic staining - eosinophil q.v.
Primary lymphoid organs
Organs in which the maturation of T and B lymphocytes take place and antigen-specific receptors are first acquired.
Primary responses
The immune response to a first encounter with antigen. The primary response is generally small, has a long induction phase or lag period, consists primarily of IgM antibodies, and generates immunologic memory.
Radioallergosorbent test (RAST)
A solid-phase radioimmunoassay for detecting IgE antibody specific for a particular allergen.
Radioimmunoassay (RIA)
A widely used technique for measurement of primary antigen-antibody interactions, and for the determination of the level of important biological substances in mixed samples. It takes advantage of the specificity of the antigen-antibody interaction and the sensitivity that derives from measurement of radioactively labelled materials.
Reticuloendothelial system
A network of phagocytic cells.
Secondary lymphoid organs
Organs in which antigen-driven proliferation and differentiation of B and T lymphocytes takes place.
Secretory component
A surface receptor on epithelial cells lining mucosal surfaces which binds dimeric IgA and transports it through the cell into mucosal secretions.
Slow-reacting substance of anaphylaxis (SRS-A)
 A group of leukotrienes released by mast cells during anaphylaxis which induces a prolonged constriction of smooth muscle. This prolonged constriction is not reversible by treatment with antihistamines.
A mechanism for producing a specific state of immunologic unresponsiveness by the induction of suppressor T cells. This type of unresponsiveness is passively transferable by suppressor T cells or their soluble products.
T cell
A lymphocyte which undergoes a developmental stage in the thymus.
Therapeutic Index

For many drugs toxicity limits the maximum dose of a drug. Therapeutic Index (TI) is a comparison of the amount of drug that causes a therapeutic effect to the amount that causes toxicity. Classically TI refers to the ratio of the dose of drug that causes adverse effects (e.g. toxic dose in 50% of subjects or TD50) to the dose that leads to the desired pharmacological effect (e.g. efficacious dose in 50% of subjects, ED50). A higher therapeutic index is preferable to a lower one: a patient would have to take a much higher dose of such a drug to reach the toxic threshold than the dose taken to elicit the therapeutic effect. The related term Therapeutic Window refers to a range of doses which optimize between efficacy and toxicity, achieving the greatest therapeutic benefit without resulting in unacceptable side-effects or toxicity. In general, it is the exposure of a given tissue to drug (i.e. drug concentration over time), rather than dose, that drives the pharmacological and toxicological effects. 

The reciprocal of the last dilution of a titration giving a measurable effect; e.g. if the last dilution giving significant agglutination is 1:128, the titer is 128.
Diminished or absent capacity to make a specific response to an antigen, usually produced as a result of contact with that antigen under nonimmunizing conditions.
Originally referred to immunization against smallpox with the less virulent cowpox (vaccinia) virus; more loosely used for any immunization against a pathogen.
Warburg Effect
In oncology, the Warburg Effect is the observation that most cancer cells predominantly produce energy by a high rate of glycolysis followed by lactic acid fermentation in the cytosol, rather than by a comparatively low rate of glycolysis followed by oxidation of pyruvate in mitochondria as in most normal cells. The latter process is aerobic (uses oxygen). Malignant, rapidly growing tumor cells typically have glycolytic rates up to 200 times higher than those of their normal tissues of origin; this occurs even if oxygen is plentiful. Otto Warburg postulated this change in metabolism is the fundamental cause of cancer, a claim now known as the Warburg Hypothesis. Today, mutations in oncogenes and tumor suppressor genes are thought to be responsible for malignant transformation, and the Warburg Effect is considered to be a result of these mutations rather than a cause.